Catalyst

Slingshot members are tracking this event:

OCREVUS (ocrelizumab) for the treatment of RMS and PPMS, and has extended the application Priority Review Designation with a targeted action date of 28th March 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
RHHBY

100%

Additional Information

Additional Relevant Details Update on 20 December 2016: PDUFA was initially set on 28 December 2016,and got extended  to 28th March 2017.
http://www.roche.com...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 29, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Ocrelizumab, Priority Review Designation, Multiple Sclerosis, Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Ocrelizumab